Expansion opportunities Seqens operates 15 manufacturing sites and 5 R&D centers across Europe, North America and Asia, offering multiple regional touchpoints for fast-tracked pilot runs, scale-up collaborations, and supply chain diversification to potential customers.

Sustainability focus The rollout of biobased ingredients such as AdvensProtect 2-EHG Green and Caprylyl Glycol signals a strong sustainability and natural-origin product strategy that can appeal to clean-label, eco-conscious brands seeking compliant and scalable ACTs, intermediates, and personal care actives.

Strategic leadership Recent leadership change with a new CEO and ongoing product launches position Seqens as a growth-oriented partner, creating an opening to discuss strategic collaborations, long-term contracts, and co-development of high-demand active ingredients.

Industry offerings With a broad portfolio in active pharmaceutical ingredients, pharmaceutical intermediates and specialty ingredients, Seqens can target pharma, personal care, and diagnostics customers seeking integrated supply, tech-enabled engineering, and custom molecule development.

Recent divestitures and focus shifts Sales of botanical actives and IVD activities to Solabia indicate portfolio adjustments, suggesting opportunities to present complementary or higher-margin alternatives within Seqens’ core capabilities, while aligning with their modernization and optimization goals.